The Human Pancreas Analysis Program (HPAP)

The past decade has seen a dramatic improvement in our ability to phenotype and molecularly profile human tissues with unprecedented resolution at the genomic, epigenomic, protein, and functional levels. The Human Pancreas Analysis Program (HPAP), part of the Human Islet Research Network and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through multiple NIH grants, is performing deep phenotyping of the human endocrine pancreas to better understand the cellular and molecular events that precede and lead to beta-cell loss and/or dysfunction in type 1 diabetes (T1D) and type 2 diabetes (T2D) as well as to accumulate, analyze, and distribute high-value data sets to the diabetes research community through the HPAP PANC-DB database (and additional details provided at that site). To this end, HPAP employs state-of-the-art technologies to perform comprehensive analyses of pancreas biology as it pertains to organ donors with T1D, autoantibody-positive donors without diabetes, donors with T2D, and control donors. Pancreas procurement and analyses take advantage of the expertise and extensive network of Organ Procurement Organizations (OPOs) and autoantibody screening centers established through the JDRF/The Lenona M. and Harry B. Helmsley Charitable Trust (HCT) – funded nPOD program. In contrast to nPOD, the major product provided by HPAP is not archived biomaterial subject to broad distribution, but rather, the delivery of extensive and high-quality molecular data sets to the diabetes research community in order to facilitate further discovery. Together, nPOD and HPAP are complementary programs that assist the diabetes community and afford the maximal opportunity for advancing knowledge about the pathogenesis of T1D and T2D.Release phs002465.v2.p1 contains 99 additional whole genome sequencing samples (sequenced with Illumina or Oxford Nanopore Technologies) and adds 148 methylation sequencing samples (from Bisulfite-Seq or EM-Seq libraries).]]>
Guidelines for normal donors: Age 20-60 years, BMI 25-40, and HbA1c < 5.7 Guidelines for T1D / T2D Donors: Age 5-60 years, BMI 20-40, HbA1c > 6.5 (though could be < 6.5 with treatment) Specific exclusion criteria include: (i) Severe renal disease (chronic), Heavy ETOH use (daily); visual inspection of pancreas, history of pancreatitis, cirrhosis, fatty live, Admission to cross clamp > 7 days, Ventilator time > 7 days, Hemodynamic instability treated with multiple pressors, Acute respiratory distress syndrome (ARDS), Positive serologies (HCV, HIV, hepatitis B), Amylase or lipase > 2X upper limits of normal, DCD donor > 45 minutes, Donor "down time" > 30 minutes, Cold ischemia time > 20 hours. Select donors may not meet all guidelines outlined above. ]]>
HPAP was launched in October 2016, first focused on the study of human T1D. In the Fall of 2020, the program was expanded to also include T2D procurement.]]>